Janosch Baumgarten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Janosch Baumgarten has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Marie Thiemann
Technische Universität Braunschweig
3 shared publications - Moritz Zimmermann
Technische Universität Braunschweig
3 shared publications - Wulf Blankenfeldt
Department Structure and Function of Proteins Helmholtz Centre for Infection Research Braunschweig Germany
3 shared publications Christina Diederich
Helmholtz Centre for Infection Research (HZI), Inhoffenstraße 7, 38124 Braunschweig, Germany
2 shared publications- Conrad Kunick
Institut für Medizinische und Pharmazeutische Chemie, Technische Universität Braunschweig, Braunschweig, Germany
2 shared publications - Maria Handke
Technische Universität Braunschweig
2 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by American Chemical Society (ACS) in ACS Bio & Med Chem Au
- Vol. 6 (5) , 626-644
Phenazine Biosynthesis Inhibitors as Pseudomonas aeruginosa Antivirulence Agents
Phenazines are redox-active secondary metabolites produced by a variety of bacteria, including Pseudomonas aeruginosa, a Gram-negative opportunistic pathogen associated with severe, often chronic infections and particularly notorious for its multiple resistance mechanisms. A major contributor to P. aeruginosa virulence and resistance is the production of phenazine-derived metabolites such as pyocyanin, which play central roles in biofilm formation, redox homeostasis, and host tissue damage. Consequently, inhibition of phenazine biosynthesis may be an attractive pathoblocker strategy aimed at attenuating bacterial virulence without exerting bactericidal pressure, thus reducing the development of drug resistance. Over the past years, considerable progress has been made in the identification and characterization of small-molecule inhibitors targeting this pathway. These advances have been driven by interdisciplinary efforts, with medicinal chemistry, chemical biology, and structural biology providing key insights into target tractability, ligand binding modes, and structure–activity relationships. In this review, we summarize recent developments in phenazine biosynthesis inhibition, highlighting representative inhibitors and discussing biological and structural data for enzymes across the pathway.
- 10 September 2026
- Published by American Chemical Society (ACS) in ACS Bio & Med Chem Au
- Vol. 6 (5) , 626-644
Open AccessPhenazine Biosynthesis Inhibitors as Pseudomonas aeruginosa Antivirulence Agents
Phenazines are redox-active secondary metabolites produced by a variety of bacteria, including Pseudomonas aeruginosa, a Gram-negative opportunistic pathogen associated with severe, often chronic infections and particularly notorious for its multiple resistance mechanisms. A major contributor to P. aeruginosa virulence and resistance is the production of phenazine-derived metabolites such as pyocyanin, which play central roles in biofilm formation, redox homeostasis, and host tissue damage. Consequently, inhibition of phenazine biosynthesis may be an attractive pathoblocker strategy aimed at attenuating bacterial virulence without exerting bactericidal pressure, thus reducing the development of drug resistance. Over the past years, considerable progress has been made in the identification and characterization of small-molecule inhibitors targeting this pathway. These advances have been driven by interdisciplinary efforts, with medicinal chemistry, chemical biology, and structural biology providing key insights into target tractability, ligand binding modes, and structure–activity relationships. In this review, we summarize recent developments in phenazine biosynthesis inhibition, highlighting representative inhibitors and discussing biological and structural data for enzymes across the pathway.
- Open Access
- 29 March 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (7) , 7390-7420
From Bones to Bugs: Structure-Based Development of Raloxifene-Derived Pathoblockers That Inhibit Pyocyanin Production in Pseudomonas aeruginosa
The human pathogen Pseudomonas aeruginosa is particularly notorious for its multiple resistance mechanisms. A new concept for anti-infectives is the "pathoblocker" approach, which targets virulence factors to disarm rather than kill pathogens and thus attenuates the development of resistance. Based on the estrogen receptor modulator raloxifene, which had previously been identified as a potential biosynthesis inhibitor of the virulence factor pyocyanin via in silico screening, analogues have been developed as pathoblockers against P. aeruginosa. These compounds reduce the production of pyocyanin by binding to the phenazine biosynthesis enzyme PhzB. Structure-activity relationships (SAR) were explored using nano differential scanning fluorimetry, isothermal titration calorimetry, and 12 X-ray cocrystal structures. Compared to raloxifene, congener 20c shows a 60-fold lower affinity for the human estrogen receptor with a 15-fold increase in pyocyanin inhibitory activity. The comprehensive structural information gathered in this study paves the way for the development of improved pathoblockers with increased potency and selectivity.
- 29 March 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (7) , 7390-7420
Open AccessFrom Bones to Bugs: Structure-Based Development of Raloxifene-Derived Pathoblockers That Inhibit Pyocyanin Production in Pseudomonas aeruginosa
The human pathogen Pseudomonas aeruginosa is particularly notorious for its multiple resistance mechanisms. A new concept for anti-infectives is the "pathoblocker" approach, which targets virulence factors to disarm rather than kill pathogens and thus attenuates the development of resistance. Based on the estrogen receptor modulator raloxifene, which had previously been identified as a potential biosynthesis inhibitor of the virulence factor pyocyanin via in silico screening, analogues have been developed as pathoblockers against P. aeruginosa. These compounds reduce the production of pyocyanin by binding to the phenazine biosynthesis enzyme PhzB. Structure-activity relationships (SAR) were explored using nano differential scanning fluorimetry, isothermal titration calorimetry, and 12 X-ray cocrystal structures. Compared to raloxifene, congener 20c shows a 60-fold lower affinity for the human estrogen receptor with a 15-fold increase in pyocyanin inhibitory activity. The comprehensive structural information gathered in this study paves the way for the development of improved pathoblockers with increased potency and selectivity.
- Open Access
- 29 October 2024
- Published by Wiley in ChemMedChem
- Vol. 19 (24) , e202400466
Substrate‐Based Ligand Design for Phenazine Biosynthesis Enzyme PhzF
The phenazine pyocyanin is an important virulence factor of the pathogen Pseudomonas aeruginosa, which is on the WHO list of antibiotic resistant “priority pathogens”. In this study the isomerase PhzF, a key bacterial enzyme of the pyocyanin biosynthetic pathway, was investigated as a pathoblocker target. The aim of the pathoblocker strategy is to reduce the virulence of the pathogen without killing it, thus preventing the rapid development of resistance. Based on crystal structures of PhzF, derivatives of the inhibitor 3–hydroxyanthranilic acid were designed. Co‐crystal structures of the synthesized derivatives with PhzF revealed spacial limitations of the binding pocket of PhzF in the closed conformation. In contrast, ligands aligned to the open conformation of PhzF provided more room for structural modifications. The intrinsic fluorescence of small 3–hydroxyanthranilic acid derivatives enabled direct affinity determinations using FRET assays. The analysis of structure‐activity relationships showed that the carboxylic acid moiety is essential for binding to the target enzyme. The results of this study provide fundamental structural insights that will be useful for the design of PhzF‐inhibitors.
- 29 October 2024
- Published by Wiley in ChemMedChem
- Vol. 19 (24) , e202400466
Open AccessSubstrate‐Based Ligand Design for Phenazine Biosynthesis Enzyme PhzF
The phenazine pyocyanin is an important virulence factor of the pathogen Pseudomonas aeruginosa, which is on the WHO list of antibiotic resistant “priority pathogens”. In this study the isomerase PhzF, a key bacterial enzyme of the pyocyanin biosynthetic pathway, was investigated as a pathoblocker target. The aim of the pathoblocker strategy is to reduce the virulence of the pathogen without killing it, thus preventing the rapid development of resistance. Based on crystal structures of PhzF, derivatives of the inhibitor 3–hydroxyanthranilic acid were designed. Co‐crystal structures of the synthesized derivatives with PhzF revealed spacial limitations of the binding pocket of PhzF in the closed conformation. In contrast, ligands aligned to the open conformation of PhzF provided more room for structural modifications. The intrinsic fluorescence of small 3–hydroxyanthranilic acid derivatives enabled direct affinity determinations using FRET assays. The analysis of structure‐activity relationships showed that the carboxylic acid moiety is essential for binding to the target enzyme. The results of this study provide fundamental structural insights that will be useful for the design of PhzF‐inhibitors.